title: Flavonoid Glycosides of Polygonum capitatum Protect against Inflammation Associated with Helicobacter pylori Infection.
abstract: The antibacterial and anti-inflammatory activities, and protective effects of extracts (flavonoid glycosides) of Polygonum capitatum were investigated to detect the evidence for the utilization of the herb in the clinical therapy of gastritis caused by H. pylori. A mouse gastritis model was established using H. pylori. According to treating methods, model mice were random assigned into a model group (MG group), a triple antibiotics group (TG group, clarithromycin, omeprazole and amoxicillin), low/middle/high concentrations of flavonoid glycosides groups (LF, MF and HF groups) and low/middle/high concentrations of flavonoid glycosides and amoxicillin groups (LFA, MFA and HFA groups). A group with pathogen-free mice was regarded as a control group (CG group). The eradicate rates of H. pylori were 100%, 93%, 89% in TG, MFA and HF groups. The serum levels of IFN-gamma and gastrin were higher in a MG group than those from all other groups (P < 0.05). The serum levels of IFN-gamma and gastrin were reduced significantly in LF, MF and HF groups (P < 0.05) while little changes were observed in LFA, MFA and HFA groups. In contrast, the serum levels of IL-4 were lower and higher in MG and CG groups compared with other groups (P<0.05). The serum levels of IL-4 were increased significantly in LF, MF and HF groups (P < 0.05) while little changes were found in LFA, MFA and HFA groups. According to pathological scores, flavonoid glycosides therapy showed better protection for gastric injuries than the combination of flavonoid glycoside and amoxicillin (P < 0.05). The results suggested that flavonoid glycoside has repairing functions for gastric injuries. The results suggest that the plant can treat gastritis and protect against gastric injuries. The flavonoid glycosides from Polygonum capitatum should be developed as a potential drug for the therapy of gastritis caused by H. pylori.
authors.affiliation: Guiyang medical college, Guiyang, 550004, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Guiyang medical college, Guiyang, 550004, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Mo
authors.affiliation: Guiyang medical college, Guiyang, 550004, China.
authors.forename: Zhaoxun
authors.initials: Z
authors.lastname: Luo
authors.affiliation: Affiliated hospital of Guiyang Medical College, Guiyang, 550004, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.affiliation: Affiliated hospital of Guiyang Medical College, Guiyang, 550004, China.
authors.forename: Chaoqin
authors.initials: C
authors.lastname: Sun
authors.affiliation: Liaocheng people's hospital, Shandong, 252000, China.
authors.forename: Ran
authors.initials: R
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D005755:Gastrins / Q000097:blood; D005756:Gastritis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006027:Glycosides / Q000494:pharmacology*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016480:Helicobacter pylori / Q000235:genetics; D007249:Inflammation / Q000517:prevention & control; D007371:Interferon-gamma / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008517:Phytotherapy; D028502:Polygonum / Q000737:chemistry*
chemical_list: D000900:Anti-Bacterial Agents; D005419:Flavonoids; D005755:Gastrins; D006027:Glycosides; D007371:Interferon-gamma